Abstract
It is now well recognized that the elderly, defined as individuals over 65 years of age, are growing in numbers and as a proportion of the total population. It is also recognized that this group disproportionately uses medicines. At the present time, for example, the elderly represent about 11% of the U.S. population and are estimated to consume 20–25% of all medications.’ Based on data from the U.S. Census Bureau,2 it is predicted that by 2030 the elderly will increase to about 21% of the U.S. population and consume more than 40% of all drugs. Equally important, the percentage growth of the “old elderly,” those 75 and over, will be even greater.3 The high prevalence of disabilities in the very old increases the chances for therapeutic misadventures. Indeed, it is widely perceived that adverse drug reactions and drug interactions are more common in the elderly than in younger patients. A recent report of the Royal College of Physicians on Adverse Drug Reactions in the Elderly4 identified inappropriate practices by treating physicians as central to this problem. On the other hand, a review by Klein et al. 5 suggests that the incidence of adverse drung reactions may not be greater in elderly patients but the opportunity for such events certainly is. Despite the extensive use of drugs by the elderly, guidance to physicians relative to this population is not widely available; i.e., dosage and precautions specific to the elderly are not commonly found in drung package inserts, therapeutic texts, or
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Vestal RE, Dawson GW: Pharmacology and aging, in Finch CE, Schneider EL (eds): Handbook of the Biology of Aging, ed 2., New York, Van Nostrand, 1985, p 744.
US Department of Commerce, Bureau of the Census, 1970 Census of the Population.
Coe RM: Comprehensive care of the elderly, in Cape RDT, Coe RM, Rossman I (eds): Fundamentals of Geriatric Medicine. New York, Raven Press, 1983, p 3.
Report of the Royal College of Physicians: Medication for the elderly. J Roy Coll Physicians London 1984; 18:7–17.
Klein LE, German PS, Levine DM: Adverse drug reactions among the elderly: A reassessment. J Am Geriatr Soc 1981; 29:525–530.
Shock NW: Aging of regulatory mechanisms, in Cape RDT, Coe RM, Rossman I (eds): Fundamentals of Geriatric Medicine. New York, Raven Press, 1983, p 51.
Fleg JL, Gerstenblith G, Lakatta, EG: Pathophysiology of the aging heart and circulation, in Messerlie FH (ed): Cardiovascular Disease in the Elderly. Boston, Martinus Nijhoff, 1984, p 11.
Abrams WB: Introducing a new drug into clinical practice. Anesthesiology 1971; 35:176–192.
Leber P: Establishing the efficacy of drugs with psychogeriatric indications, in Crook T, Ferris S, Bartus, R (eds): Assessment in Geriatric Psychopharmacology. New Canaan, CT, Mark Powley Associates, 1983, p 1.
Anello C: FDA principles on clinical investigations. FDA Papers 1970; 4:14–15; 23–24.
FDA Guidelines: General considerations for the clinical evaluation of drugs. US Dept. of Health, Education, and Welfare, September 1977.
Friedman LM, Furberg C, DeMets DL (eds): Fundamentals of Clinical Trials. Boston, John Wright, PSG Inc, 1982.
Abrams WB: The development of clinical protocols, in Finkel MJ (ed): Factors Influencing Clinical Research Success. Mount Kisco, NY, Futura Publishing Co., 1976, p 7.
Williams ME, Retchin SM: Clinical geriatric research: Still in adolescence. J Am Geriatr Soc 1984; 32:851–857.
FDA Discussion Paper on Testing of Drugs in the Elderly, Department of Health and Human Services, Public Health Service, Food and Drug Administration. Memorandum from Temple R, September 30, 1983.
Workshop on Proposed FDA Guidelines for Clinical Evaluation of Drugs Being Developed for Use in the Elderly, sponsored by the American Society for Clinical Pharmacology and Therapeutics and Food and Drug Administration, Rockville, MD, Sept. 13–14, 1984, cochairmen: Reidenberg MJ, Abrams WB.
Crooks, J: Report prepared for the Committee on Safety of Medicines, England.
Rotenberg KS (Food and Drug Administration): IND/NDA Guidelines for Bioavailability Submission. Presented at 20th Annual International Industrial Pharmacy Conf., Austin, Texas, Feb. 24, 1981.
Lindeman RD, Klingler EL, Jr: Fluid, electrolyte, trace mineral and renal problems in the elderly: With emphasis directed at the effects of renal impairment on drug pharmacology, in Vestal RE (ed): Drug Treatment in the Elderly. Australia, ADIS Health Sc. Press, 1984, p 116.
Bjornsson TD: Use of serum creatinine concentrations to determine renal function. Clin Pharmacokin 1979; 4:220–222.
Rodda RE, Davis RL: Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 1980; 28:247–252.
Kane RA, Kane RL: Assessing the Elderly: A Practical Guide to Measurement. Lexington, MA, Lexington Books, 1981.
Crook T, Ferris S, Bartus R (eds): Assessment in Geriatric Psychopharmacology. New Canaan, CT, Mark Powley Associates, 1983.
Vestal RE, Wood AJJ, Shand DG: Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 1979; 26:181–186.
Castleden CM, George, CF: The effect of ageing on the hepatic clearance of propranolol. BrJ Clin Pharmacol 1979; 7:49–54.
Friedman JA, Chalmers TC, Smith H, et al.: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. N Engl J Med 1978; 299:690–694.
National Center for Health Statistics: Chronic Conditions and Limitations of Activity and Mobility: United States, July 1967 Vital and Health Statistics, PHS Pub. No. 1000-Series 10-No. 61. Washington, DC, Public Health Service, US Government Printing Office, 1971.
Box GED, Tian GC: Bayesian Inference in Statistical Analysis, Reading, MA, Addison Wesley Publishing Co, 1973.
Katz S, Branch LG, Branson MH, Papsidero JA, Beck JC, Greer DS: Active life expectancy. N Engl J Med 1983; 309:1218–1224.
Katz S, Akpom CA: A measure of primary sociobiological functions. Int J Health Sery 1976; 6:493–508.
The Norwegian Multicentre Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N EnglJ Med 1981; 304:801–807.
Beta-Blocker Heart Attack Trial (BHAT) Research Group Report: A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results.JAMA 1982; 247:1707–1717.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: 1. Reduction in incidence of coronary heart disease, and 2. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:351–364, 365–374.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Publishing Corporation
About this chapter
Cite this chapter
Abrams, W.B., Rodda, B.E. (1986). Clinical Trial Design—Industry Perspective. In: Cutler, N.R., Narang, P.K. (eds) Drug Studies in the Elderly. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1253-6_18
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1253-6_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1255-0
Online ISBN: 978-1-4684-1253-6
eBook Packages: Springer Book Archive